Urinary Incontinence - Pipeline Review, H2 2014

Published: Oct, 2014 | Pages: 62 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Urinary Incontinence - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Urinary Incontinence - Pipeline Review, H2 2014', provides an overview of the Urinary Incontinence's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Urinary Incontinence, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Urinary Incontinence and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Urinary Incontinence
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Urinary Incontinence and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Urinary Incontinence products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Urinary Incontinence pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Urinary Incontinence
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Urinary Incontinence pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Urinary Incontinence Overview 7
Therapeutics Development 8
Pipeline Products for Urinary Incontinence - Overview 8
Pipeline Products for Urinary Incontinence - Comparative Analysis 9
Urinary Incontinence - Therapeutics under Development by Companies 10
Urinary Incontinence - Therapeutics under Investigation by Universities/Institutes 11
Urinary Incontinence - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Urinary Incontinence - Products under Development by Companies 15
Urinary Incontinence - Products under Investigation by Universities/Institutes 16
Urinary Incontinence - Companies Involved in Therapeutics Development 17
Allergan, Inc. 17
Astellas Pharma Inc. 18
Beech Tree Labs, Inc. 19
Cook MyoSite Incorporated 20
Evotec AG 21
FemmePharma Global Healthcare, Inc. 22
Innovacell Biotechnologie AG 23
Recordati S.p.A. 24
TheraVida, Inc. 25
Urinary Incontinence - Therapeutics Assessment 26
Assessment by Monotherapy Products 26
Assessment by Combination Products 27
Assessment by Target 28
Assessment by Mechanism of Action 30
Assessment by Route of Administration 32
Assessment by Molecule Type 34
Drug Profiles 36
(mirabegron + solifenacin succinate) - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
(tolterodine + pilocarpine) - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
BTL-ui - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Cell Therapy for Urinary Incontinence - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
ICES-13 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
oxybutynin hydrochloride - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Prof-003 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
REC-1819 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
senrebotase - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Small Molecule to Antagonize P2X3 and P2X2/3 for Inflammatory Pain, Neuropathic Pain and Urinary Incontinence - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Stem Cell Therapy for CAD, Urinary Incontinence and Fecal Incontinence - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
THVD-202 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Urinary Incontinence - Recent Pipeline Updates 50
Urinary Incontinence - Dormant Projects 53
Urinary Incontinence - Discontinued Products 54
Urinary Incontinence - Product Development Milestones 55
Featured News & Press Releases 55
Jul 03, 2013: Impax Laboratories Confirms Patent Challenge Relating to Generic TOVIAZ 4 mg and 8 mg 55
Jan 03, 2013: TheraVida Announces Positive Top-line Phase II Results For Tolenix In Patients With Overactive Bladder And Urge Urinary Incontinence 55
Nov 06, 2012: Beech Tree Labs Completes Phase IIa Urinary Incontinence Clinical Trial Using UISH001 56
Mar 15, 2012: Innovacell To Present Phase IIb Trial Results Of ICES13 At MedTech Investing Europe Conference 56
Dec 05, 2011: Pfizer's Toviaz Shows Positive Top-Line Primary Endpoint Result In Study Of Overactive Bladder In Vulnerable Elderly Patients 57
Nov 08, 2011: Pfizer Announces Positive Top-Line Primary Endpoint Results Of Toviaz In Overactive Bladder Including Nocturnal Urinary Urgency 57
Aug 30, 2011: Innovacell passes a further milestone 58
May 16, 2011: TheraVida Initiates Phase II Trial Of THVD-201 For Overactive Bladder And Urinary Incontinence 59
Apr 13, 2011: Beech Tree Labs Initiates Urinary Incontinence Trial 59
Mar 22, 2011: TheraVida Announces Positive Results From Phase I Trial Of THVD-201 60
Appendix 61
Methodology 61
Coverage 61
Secondary Research 61
Primary Research 61
Expert Panel Validation 61
Contact Us 62
Disclaimer 62

List of Tables
Number of Products under Development for Urinary Incontinence, H2 2014 8
Number of Products under Development for Urinary Incontinence - Comparative Analysis, H2 2014 9
Number of Products under Development by Companies, H2 2014 10
Number of Products under Investigation by Universities/Institutes, H2 2014 11
Comparative Analysis by Late Stage Development, H2 2014 12
Comparative Analysis by Clinical Stage Development, H2 2014 13
Comparative Analysis by Early Stage Development, H2 2014 14
Products under Development by Companies, H2 2014 15
Products under Investigation by Universities/Institutes, H2 2014 16
Urinary Incontinence - Pipeline by Allergan, Inc., H2 2014 17
Urinary Incontinence - Pipeline by Astellas Pharma Inc., H2 2014 18
Urinary Incontinence - Pipeline by Beech Tree Labs, Inc., H2 2014 19
Urinary Incontinence - Pipeline by Cook MyoSite Incorporated, H2 2014 20
Urinary Incontinence - Pipeline by Evotec AG, H2 2014 21
Urinary Incontinence - Pipeline by FemmePharma Global Healthcare, Inc., H2 2014 22
Urinary Incontinence - Pipeline by Innovacell Biotechnologie AG, H2 2014 23
Urinary Incontinence - Pipeline by Recordati S.p.A., H2 2014 24
Urinary Incontinence - Pipeline by TheraVida, Inc., H2 2014 25
Assessment by Monotherapy Products, H2 2014 26
Assessment by Combination Products, H2 2014 27
Number of Products by Stage and Target, H2 2014 29
Number of Products by Stage and Mechanism of Action, H2 2014 31
Number of Products by Stage and Route of Administration, H2 2014 33
Number of Products by Stage and Molecule Type, H2 2014 35
Urinary Incontinence Therapeutics - Recent Pipeline Updates, H2 2014 50
Urinary Incontinence - Dormant Projects, H2 2014 53
Urinary Incontinence - Discontinued Products, H2 2014 54